The impact of the Cancer Genome Atlas on lung cancer

Translational Research : the Journal of Laboratory and Clinical Medicine
Jeremy T-H ChangR Stephanie Huang

Abstract

The Cancer Genome Atlas (TCGA) has profiled more than 10,000 samples derived from 33 types of cancer to date, with the goal of improving our understanding of the molecular basis of cancer and advancing our ability to diagnose, treat, and prevent cancer. This review focuses on lung cancer as it is the leading cause of cancer-related mortality worldwide in both men and women. Particularly, non-small cell lung cancers (including lung adenocarcinoma and lung squamous cell carcinoma) were evaluated. Our goal was to demonstrate the impact of TCGA on lung cancer research under 4 themes: diagnostic markers, disease progression markers, novel therapeutic targets, and novel tools. Examples are given related to DNA mutation, copy number variation, messenger RNA, and microRNA expression along with methylation profiling.

References

Dec 31, 1997·Science·C D ChungK Shuai
Jul 8, 1998·Proceedings of the National Academy of Sciences of the United States of America·T KamijoC J Sherr
Nov 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·A R KarpfD A Jones
May 8, 2002·The Journal of Clinical Investigation·Christian W Schindler
Feb 26, 2003·Genes & Development·Nuno André Faustino, Thomas A Cooper
Apr 16, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·David J StewartPeter MacLeod
Nov 3, 2004·Cancer Research·Julian P Venables
Oct 8, 2005·Seminars in Oncology·Rainer ClausMichael Lübbert
Apr 8, 2006·Genes & Development·Andrew D Sharrocks
Nov 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D Neil HayesMatthew Meyerson
Jun 5, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ester FonsattiMichele Maio
Sep 14, 2007·Nature Reviews. Cancer·John Stingl, Carlos Caldas
Dec 1, 2007·Cell Death and Differentiation·A EramoR De Maria
Apr 22, 2008·International Journal of Cancer. Journal International Du Cancer·Carlo Stresemann, Frank Lyko
Aug 5, 2008·Trends in Immunology·Malini RaghavanLarry Robert Peters
Aug 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Emily C BrantleyEtty N Benveniste
Sep 2, 2008·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Hiromasa YamamotoTetsuya Mitsudomi
Nov 19, 2008·Nature Reviews. Genetics·Zhong WangMichael Snyder
Dec 20, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Kenichi SudaTetsuya Mitsudomi
Feb 26, 2009·Cell·Richard W Carthew, Erik J Sontheimer
Jan 1, 2008·Cytogenetic and Genome Research·I Johansson, M Ingelman-Sundberg
Jun 16, 2009·Cell·Scott ValastyanRobert A Weinberg
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Dec 17, 2009·PLoS Computational Biology·Daniel RamsköldRickard Sandberg
Mar 10, 2010·Expert Reviews in Molecular Medicine·Charles Lee, Stephen W Scherer
May 28, 2010·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Sara CabodiPaola Defilippi
Oct 29, 2010·The New England Journal of Medicine·Eunice L KwakA John Iafrate
Mar 11, 2011·Trends in Molecular Medicine·Yijing HeHoward L McLeod

❮ Previous
Next ❯

Citations

Jul 2, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Ting-Yuan David ChengMary E Reid
Dec 19, 2017·Journal of Thoracic Imaging·Varut Vardhanabhuti, Michael D Kuo
Aug 31, 2018·International Journal of Computer Assisted Radiology and Surgery·Victor Andrew A AntonioShigehiko Kanaya
Nov 28, 2017·Acta Oncologica·Hannah H VestergaardUlrik N Lassen
Oct 17, 2019·International Journal of Cancer. Journal International Du Cancer·Sen YangQingyi Wei
Sep 8, 2017·Journal of the American Podiatric Medical Association·Leonard A Levy
Jul 15, 2020·Journal of Cancer Research and Clinical Oncology·Anjali LathwalGajendra Pal Singh Raghava
Oct 13, 2018·International Journal of Molecular Sciences·Chin-Sheng HungRuo-Kai Lin
Jun 3, 2017·Briefings in Bioinformatics·Jocelyn GalEmmanuel Chamorey
Aug 23, 2019·Journal of Virology·Anna Eleonora KaragianniDavid J Griffiths
Jun 13, 2020·Journal of Clinical Medicine·Roberto GasparriLorenzo Spaggiari
Nov 18, 2020·Scientific Reports·Deogratias MzurikwaoChee Siang Ang
Mar 9, 2021·Computational and Mathematical Methods in Medicine·Min ZhangCui Ma
Apr 20, 2021·Frontiers in Cell and Developmental Biology·Wei JiangYu Feng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Alternative splicing

Alternative splicing a regulated gene expression process that allows a single genetic sequence to code for multiple proteins. Here is that latest research.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Related Papers

The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology
Fang Lu, Hong-Tao Zhang
Zhongguo fei ai za zhi = Chinese journal of lung cancer
Na Han, Hongyang Lu
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
William JacotJérôme Solassol
© 2021 Meta ULC. All rights reserved